Skip to main content
Erschienen in: Annals of Surgical Oncology 8/2019

03.05.2019 | Thoracic Oncology

Tumor Volume Is Better Than Diameter for Predicting the Prognosis of Patients with Early-Stage Non-small Cell Lung Cancer

verfasst von: Hao-jun Xie, MS, Xu Zhang, MD, PhD, Yun-xian Mo, MD, Hao Long, MD, PhD, Tie-hua Rong, MD, Xiao-dong Su, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

This study aimed to investigate whether tumor volume (TV) is better than diameter for predicting the prognosis of patients with early-stage non-small cell lung cancer (NSCLC) after complete resection.

Methods

This study retrospectively reviewed the clinicopathologic characteristics of 274 patients with early-stage NSCLC who had received pretreatment computed tomography (CT) scans and complete resection. TV was semi-automatically measured from CT scans using an imaging software program. The optimal cutoff of TV was determined by X-tile software. Disease-free survival (DFS) and overall survival (OS) were assessed by the Kaplan–Meier method. The prognostic significance of TV and other variables was assessed by Cox proportional hazards regression analysis.

Results

Using 3.046 cm3 and 8.078 cm3 as optimal cutoff values of TV, the patients were separated into three groups. A larger TV was significantly associated with poor DFS and OS in the multivariable analysis. Kaplan–Meier curves of DFS and OS showed significant differences on the basis of TV among patients with stage 1a disease, greatest tumor diameter (GTD) of 2 cm or smaller, and GTD of 2–3 cm, respectively. Using two TV cutoff points, three categories of TV were created. In 54 cases (19.7%), patients migrated from the GTD categories of 2 cm or smaller, 2–3 cm, and larger than 3 cm into the TV categories of 3.046 cm3 or smaller, 3.046–8.078 cm3, and larger than 8.078 cm3.

Conclusion

TV is an independent prognostic factor of DFS and OS for early-stage NSCLC. The findings show that TV is better than GTD for predicting the prognosis of patients with early-stage NSCLC.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Rami-Porta R, Bolejack V, Crowley J, et al. The IASLC lung cancer staging project proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2015;10:990–1003.CrossRefPubMed Rami-Porta R, Bolejack V, Crowley J, et al. The IASLC lung cancer staging project proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2015;10:990–1003.CrossRefPubMed
2.
Zurück zum Zitat Zhao B, Schwartz LH, Moskowitz CS, Ginsberg MS, Rizvi NA, Kris MG. Lung cancer: computerized quantification of tumor response: initial results. Radiology. 2006;241:892–8.CrossRefPubMed Zhao B, Schwartz LH, Moskowitz CS, Ginsberg MS, Rizvi NA, Kris MG. Lung cancer: computerized quantification of tumor response: initial results. Radiology. 2006;241:892–8.CrossRefPubMed
3.
Zurück zum Zitat Suzuki C, Jacobsson H, Hatschek T. Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics. 2008;28:329–44.CrossRefPubMed Suzuki C, Jacobsson H, Hatschek T. Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics. 2008;28:329–44.CrossRefPubMed
4.
Zurück zum Zitat Jennings SG, Winer-Muram HT, Tarver RD, Farber MO. Lung tumor growth: assessment with CT: comparison of diameter and cross-sectional area with volume measurements. Radiology. 2004;231:866–71.CrossRefPubMed Jennings SG, Winer-Muram HT, Tarver RD, Farber MO. Lung tumor growth: assessment with CT: comparison of diameter and cross-sectional area with volume measurements. Radiology. 2004;231:866–71.CrossRefPubMed
5.
Zurück zum Zitat Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39–51.CrossRefPubMed Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39–51.CrossRefPubMed
6.
Zurück zum Zitat Gietema HA, Wang Y, Xu D, et al. Pulmonary nodules detected at lung cancer screening: interobserver variability of semiautomated volume measurements. Radiology. 2006;241:251–7.CrossRefPubMed Gietema HA, Wang Y, Xu D, et al. Pulmonary nodules detected at lung cancer screening: interobserver variability of semiautomated volume measurements. Radiology. 2006;241:251–7.CrossRefPubMed
7.
Zurück zum Zitat 7. Zhao B, Oxnard GR, Moskowitz CS, et al. A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Clin Cancer Res. 2010;16:4647–53.CrossRefPubMedPubMedCentral 7. Zhao B, Oxnard GR, Moskowitz CS, et al. A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Clin Cancer Res. 2010;16:4647–53.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat 8. Mozley PD, Schwartz LH, Bendtsen C, Zhao B, Petrick N, Buckler AJ. Change in lung tumor volume as a biomarker of treatment response: a critical review of the evidence. Ann Oncol. 2010;21:1751–5.CrossRefPubMed 8. Mozley PD, Schwartz LH, Bendtsen C, Zhao B, Petrick N, Buckler AJ. Change in lung tumor volume as a biomarker of treatment response: a critical review of the evidence. Ann Oncol. 2010;21:1751–5.CrossRefPubMed
9.
Zurück zum Zitat 9. Mozley PD, Bendtsen C, Zhao B, et al. Measurement of tumor volumes improves RECIST-based response assessments in advanced lung cancer. Transl Oncol. 2012;5:19–25.CrossRefPubMedPubMedCentral 9. Mozley PD, Bendtsen C, Zhao B, et al. Measurement of tumor volumes improves RECIST-based response assessments in advanced lung cancer. Transl Oncol. 2012;5:19–25.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat 10. Nishino M, Guo M, Jackman DM, et al. CT tumor volume measurement in advanced non-small cell lung cancer: performance characteristics of an emerging clinical tool. Acad Radiol. 2011;18:54–62.CrossRefPubMed 10. Nishino M, Guo M, Jackman DM, et al. CT tumor volume measurement in advanced non-small cell lung cancer: performance characteristics of an emerging clinical tool. Acad Radiol. 2011;18:54–62.CrossRefPubMed
11.
Zurück zum Zitat 11. Dehing-Oberije C, De Ruysscher D, van der Weide H, et al. Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small cell lung cancer patients treated with (chemo) radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:1039–44.CrossRefPubMed 11. Dehing-Oberije C, De Ruysscher D, van der Weide H, et al. Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small cell lung cancer patients treated with (chemo) radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:1039–44.CrossRefPubMed
12.
Zurück zum Zitat 12. Nishino M, Dahlberg SE, Cardarella S, et al. Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI. J Thorac Oncol. 2013;8:1059–68.CrossRefPubMedPubMedCentral 12. Nishino M, Dahlberg SE, Cardarella S, et al. Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI. J Thorac Oncol. 2013;8:1059–68.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat 13. Su XD, Xie HJ, Liu QW, Mo YX, Long H, Rong TH. The prognostic impact of tumor volume on stage I non-small cell lung cancer. Lung Cancer. 2017;104:91–7.CrossRefPubMed 13. Su XD, Xie HJ, Liu QW, Mo YX, Long H, Rong TH. The prognostic impact of tumor volume on stage I non-small cell lung cancer. Lung Cancer. 2017;104:91–7.CrossRefPubMed
14.
Zurück zum Zitat Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Pathology and genetics of tumours of the lung, pleura, thymus, and heart. In: World Health Organization classification of tumours. Lyon, France: IARC Press; 2004. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Pathology and genetics of tumours of the lung, pleura, thymus, and heart. In: World Health Organization classification of tumours. Lyon, France: IARC Press; 2004.
15.
Zurück zum Zitat 15. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252–9.CrossRef 15. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252–9.CrossRef
16.
Zurück zum Zitat 16. Hyun SH, Choi JY, Kim K, et al. Volume-based parameters of 18 F-fluorodeoxy glucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection. Ann Surg. 2013;257:364–70.CrossRefPubMed 16. Hyun SH, Choi JY, Kim K, et al. Volume-based parameters of 18 F-fluorodeoxy glucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection. Ann Surg. 2013;257:364–70.CrossRefPubMed
17.
Zurück zum Zitat 17. Takenaka T, Yamazaki K, Miura N, Mori R, Takeo S. The prognostic impact of tumor volume in patients with clinical stage IA non-small cell lung cancer. J Thorac Oncol. 2016;11:1074–80.CrossRefPubMed 17. Takenaka T, Yamazaki K, Miura N, Mori R, Takeo S. The prognostic impact of tumor volume in patients with clinical stage IA non-small cell lung cancer. J Thorac Oncol. 2016;11:1074–80.CrossRefPubMed
18.
Zurück zum Zitat Hyun SH, Ahn HK, Ahn MJ, et al. Volume-based assessment with 18F-FDG PET/CT improves outcome prediction for patients with stage IIIA-N2 non-small cell lung cancer. AJR Am J Roentgenol. 2015;205:623–8.CrossRefPubMed Hyun SH, Ahn HK, Ahn MJ, et al. Volume-based assessment with 18F-FDG PET/CT improves outcome prediction for patients with stage IIIA-N2 non-small cell lung cancer. AJR Am J Roentgenol. 2015;205:623–8.CrossRefPubMed
19.
Zurück zum Zitat 19. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552–9.CrossRefPubMed 19. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552–9.CrossRefPubMed
20.
Zurück zum Zitat Scott WJ, Howington J, Feigenberg S, et al. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd ed). Chest. 2007;132:234S–42S.CrossRefPubMed Scott WJ, Howington J, Feigenberg S, et al. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd ed). Chest. 2007;132:234S–42S.CrossRefPubMed
21.
Zurück zum Zitat Strauss GM, Herndon JE, Maddaus MA, et al.Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small cell lung cancer: CALGB 9633 with the cancer and leukemia group B, radiation therapy oncology group, and north central cancer treatment group study groups. J Clin Oncol. 2008;26:5043–51.CrossRefPubMedPubMedCentral Strauss GM, Herndon JE, Maddaus MA, et al.Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small cell lung cancer: CALGB 9633 with the cancer and leukemia group B, radiation therapy oncology group, and north central cancer treatment group study groups. J Clin Oncol. 2008;26:5043–51.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMed Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMed
Metadaten
Titel
Tumor Volume Is Better Than Diameter for Predicting the Prognosis of Patients with Early-Stage Non-small Cell Lung Cancer
verfasst von
Hao-jun Xie, MS
Xu Zhang, MD, PhD
Yun-xian Mo, MD
Hao Long, MD, PhD
Tie-hua Rong, MD
Xiao-dong Su, MD, PhD
Publikationsdatum
03.05.2019
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 8/2019
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07412-w

Weitere Artikel der Ausgabe 8/2019

Annals of Surgical Oncology 8/2019 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.